Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to MAINZ BIOMED N.V. in $25.875 Million U.S. Follow-On Public Offering
Press Release – New York, NY – January 28, 2022 – Sichenzia Ross Ference LLP congratulates MAINZ BIOMED N.V. (the “Company”) (NASDAQ: MYNZ ), a molecular genetics diagnostic company specializing in the early detection of cancer, on the final closing of its follow-on public offering on January 28, 2022.
The Company raised $25.875 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 1,725,000 ordinary shares (which includes the underwriter’s option to purchase up to 225,000 additional ordinary shares at the offering price to cover over-allotments) at a public offering price of $15.00 per share. The ordinary shares commenced trading on the Nasdaq Capital Market on November 5, 2021 under the ticker symbol “MYNZ”.
Boustead Securities, LLC acted as the sole underwriter for the offering and the Firm acted as legal counsel to the underwriter. The Sichenzia Ross Ference LLP team was led by Senior Partner, Benjamin Tan.
- Sichenzia Ross Ference LLP Represents Madison Global Partners, LLC in $8.2 Million Simultaneous Registered Direct Offering and Private Placement of Securities of authID Inc. - June 2, 2023
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp.in $1.7 Million At-The-Market Offering Facility with SciSparc Ltd. - May 24, 2023
- Sichenzia Ross Ference LLP Represents Sunshine Biopharma, Inc. in $5.0 Million Private Placement Priced At-the-Market - May 16, 2023